Search research articles
Contact Us
Filters
Showing results (271-280 of 309) with videos related to
Page
of 31
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2012
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
P Karlsson, B F Cole, B H Chua, et al.
The Lancet. Oncology
|
October 25, 2011
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Meredith M Regan, Patrick Neven, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2016
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Jacquie H Chirgwin, Anita Giobbie-Hurder, Alan S Coates, et al.
Lancet (London, England)
|
May 4, 2013
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
Jack Cuzick, Ivana Sestak, Bernardo Bonanni, et al.
Breast Cancer Research and Treatment
|
October 28, 2008
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Olivia Pagani, Shari Gelber, Edda Simoncini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Marco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
British Journal of Cancer
|
November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
J Bernhard, D Zahrieh, J J Zhang, et al.
Breast (Edinburgh, Scotland)
|
January 8, 2014
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
N McCarthy, F Boyle, N Zdenkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M Rabaglio, Z Sun, K N Price, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
Page
of 31
Search research articles
Search
Showing results (271-280 of 309) with videos related to
Sort By:
Page
of 31
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2012
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
P Karlsson, B F Cole, B H Chua, et al.
The Lancet. Oncology
|
October 25, 2011
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Meredith M Regan, Patrick Neven, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2016
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Jacquie H Chirgwin, Anita Giobbie-Hurder, Alan S Coates, et al.
Lancet (London, England)
|
May 4, 2013
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
Jack Cuzick, Ivana Sestak, Bernardo Bonanni, et al.
Breast Cancer Research and Treatment
|
October 28, 2008
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Olivia Pagani, Shari Gelber, Edda Simoncini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Marco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
British Journal of Cancer
|
November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
J Bernhard, D Zahrieh, J J Zhang, et al.
Breast (Edinburgh, Scotland)
|
January 8, 2014
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
N McCarthy, F Boyle, N Zdenkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M Rabaglio, Z Sun, K N Price, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
Page
of 31